Who is sponsoring NCT04234438?

NCT04234438 is sponsored by Ankara Universitesi Teknokent.

What condition does NCT04234438 study?

NCT04234438 studies Retinitis Pigmentosa, Cystoid Macular Edema.

Is NCT04234438 still recruiting?

NCT04234438 is currently completed. Last updated 23 January 2020.

Last reviewed 2020-01-23 · How we verify

NCT04234438: SL-MPL

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Management of Cystoid Macular Edema Secondary to Retinitis Pigmentosa Via Subliminal Micropulse Yellow Laser

Completed NA Last updated 23 January 2020

What this trial tests

NA trial testing SL-MPL treatment protocol was performed with a 577 nm yellow laser (EasyRet, Quantel Medical, Cedex, France) in Retinitis Pigmentosa in 32 participants. Completed in 30 December 2019.

Timeline

1 January 2018

Primary endpoint
30 October 2019

30 December 2019

Quick facts

Lead sponsor	Ankara Universitesi Teknokent
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	32
Start date	1 January 2018
Primary completion	30 October 2019
Estimated completion	30 December 2019
Sites	2 locations across Turkey (Türkiye)

Drugs / interventions tested

SL-MPL treatment protocol was performed with a 577 nm yellow laser (EasyRet, Quantel Medical, Cedex, France)

Conditions studied

Retinitis Pigmentosa — all drugs for Retinitis Pigmentosa →
Cystoid Macular Edema — all drugs for Cystoid Macular Edema →

Sponsor

Ankara Universitesi Teknokent — full company profile →

Who can join

Adults 18 to 70, any sex, with Retinitis Pigmentosa or Cystoid Macular Edema. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Purpose: To investigate the effects of subliminal micropulse yellow laser application on central macular thickness and best corrected visual acuity in cystoid macular edema secondary to retinitis pigmentosa patients.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Management of cystoid macular edema secondary to retinitis pigmentosa via subliminal micropulse yellow laser.
Arslan U. · · 2021 · cited 5× · PMID 32363437 · DOI 10.1007/s10103-020-03031-0

Verify or expand the search:

Other recruiting trials for Retinitis Pigmentosa

Currently open trials in the same condition.

NCT06891885 — A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years · Phase 1, PHASE2 · recruiting
NCT07408232 — A Phase 1/2 Study in Healthy Volunteers and Participants With Autosomal Dominant Retinitis Pigmentosa (RHO-adRP) · Phase 1, PHASE2 · recruiting
NCT07228793 — Natural History Study of Patients With EYS-Associated RP · recruiting
NCT06319872 — The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration · Phase 1 · recruiting
NCT06936787 — An Open-label, Dose-ascending Study of IGT001 for Retinitis Pigmentosa · Phase 1 · recruiting

Other Ankara Universitesi Teknokent trials

Trials by the same sponsor.

NCT04224207 — Management of Retinitis Pigmentosa by Mesenchymal Stem Cells by Wharton's Jelly Derived Mesenchymal Stem Cells · Phase 3 · completed
NCT04877067 — Therapy of Toxic Optic Neuropathy Via Combination of Stem Cells With Electromagnetic Stimulation · Phase 3 · completed
NCT05800301 — Management of Retinitis Pigmentosa Via Combination of Wharton's Jelly-derived Mesenchymal Stem Cells and Magnovision · Phase 3 · completed
NCT04224831 — Treatment of Chronic Central Serous Chorioretinopathy Via Electromagnetic Stimulation and Platelet- Rich Plasma · NA · completed
NCT04242719 — Management of Deep Retinal Capillary Ischemia by Electromagnetic Stimulation and Platelet- Rich Plasma · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04234438 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ankara Universitesi Teknokent
Last refreshed: 23 January 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04234438.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing